After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Vertex Pharmaceuticals, Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Vertex Pharmaceuticals, Inc. is $107.25B. A total of 0.86 million shares were traded on the day, compared to an average of 1.32M shares.
In the most recent transaction, Arbuckle Stuart A sold 5,034 shares of VRTX for 425.70 per share on Feb 26 ’24. After the transaction, the EVP, COO now owns 49,691 company shares. In a previous transaction on Feb 26 ’24, ALTSHULER DAVID sold 4,239 shares at 425.70 per share. VRTX shares that EVP, Global Research and CSO owns now total 25,813.
Among the insiders who sold shares, Sachdev Amit disposed of 3,004 shares on Feb 26 ’24 at a per-share price of $425.70. This resulted in the EVP Chief Patient & Ext Af Off holding 55,325 shares of VRTX after the transaction. In another insider transaction, Ambrose Kristen sold 883 shares at $425.70 per share on Feb 26 ’24. Company shares held by the SVP & Chief Accounting Officer now total 7,965.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, VRTX has a high of $448.40 and a low of $296.09.
As of this writing, VRTX has an earnings estimate of $4.05 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of $4.44 per share and a lower estimate of $3.37. The company reported an EPS of $4.08 in the last quarter, which was 2.80% higher than expectations of $3.97.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $967.40M in debt and $2.14B in liabilities at the time. Its Book Value Per Share was $68.22, while its Total Shareholder’s Equity was $10.10B.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.07.
